53668-36-3

Basic information

• Product Name: 4-AMINO-N-ISOBUTYLBENZENESULFONAMIDE
• Synonyms: 4-AMINO-N-ISOBUTYLBENZENESULFONAMIDE;4-amino-N-(2-methylpropyl)benzenesulfonamide
• CAS NO: 53668-36-3
• Molecular Formula: C₁₀H₁₆N₂O₂S
• Molecular Weight: 228.31124
• Mol File: 53668-36-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-AMINO-N-ISOBUTYLBENZENESULFONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINO-N-ISOBUTYLBENZENESULFONAMIDE(53668-36-3)
• EPA Substance Registry System: 4-AMINO-N-ISOBUTYLBENZENESULFONAMIDE(53668-36-3)

Safety Data

• Hazardous Substances Data: 53668-36-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Amino-N-isobutylbenzenesulfonamide is used as an intermediate in the synthesis of sulfonamide drugs for its antibacterial properties, contributing to the development of medications that combat bacterial infections.
Used in Urinary Tract Infection Treatment:
In the medical field, 4-Amino-N-isobutylbenzenesulfonamide is used as an active ingredient in medications for treating urinary tract infections, where it inhibits bacterial growth, thereby alleviating symptoms and promoting recovery.
Used in Hypertension Management:
4-Amino-N-isobutylbenzenesulfonamide is utilized as a diuretic component in antihypertensive medications, reducing the reabsorption of salt and water in the kidneys, which helps lower blood pressure.
Used in Research and Development:
4-Amino-N-isobutylbenzenesulfonamide is employed in scientific research for its potential antitumor and anti-inflammatory activities, with ongoing studies aimed at exploring its therapeutic potential in various conditions.
It is crucial to handle 4-Amino-N-isobutylbenzenesulfonamide with care due to its potential to cause irritation to the skin, eyes, and respiratory system if not properly managed.

Upstream product

• 24939-24-0 4-aminobenzenesulfonyl chloride 
• 78-81-9 isobutylamine 
• 6752-38-1 4-chlorosulfonylbenzene isocyanate 
• 89840-80-2 N-isobutyl-4-nitrobenzenesulfonamide 
• 98-74-8 4-Nitrobenzenesulfonyl chloride 

Downstream Products

• 169280-56-2 4-amino-N-(2R,3S)(3-amino-2-hydroxy-4-phenylbutyl)-N-isobutylbenzenesulfonamide 
• 183004-94-6 3-S-(N-tert-butyloxyformamido)-[2R-hydroxy-1-[(4-aminophenylsulfonyl)(2-methylpropyl)]amino]-4-phenylbutane 
• 608523-57-5 6-[4-(Isobutylsulfamoyl)phenylazo]pyridoxal-5-phosphate 

Relevant articles and documents

Potent and selective N-(4-sulfamoylphenyl)thiourea-based GPR55 agonists

To date, many known G protein-coupled receptor 55 (GPR55) ligands are those identified among the cannabinoids. In order to further study the function of GPR55, new potent and selective ligands are needed. In this study, we utilized the screening results from PubChem bioassay AID 1961 which reports the results of Image-based HTS for Selective Agonists of GPR55. Three compounds, CID1792579, CID1252842 and CID1011163, were further evaluated and used as a starting point to create a series of nanomolar potency GPR55 agonists with N-(4-sulfamoylphenyl)thiourea scaffold. The GPR55 activity of the compounds were screened by using a commercial β-arrestin PathHunter assay and the potential compounds were further evaluated by using a recombinant HEK cell line exhibiting GPR55-mediated effects on calcium signalling. The designed compounds were not active when tested against various endocannabinoid targets (CB1R, CB2R, FAAH, MGL, ABHD6 and ABHD12), indicating compounds' selectivity for the GPR55. Finally, structure-activity relationships of these compounds were explored.

PROCESS FOR THE PREPARATION OF SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS

The present invention relates to a process for the preparation of sulfonamides useful as retroviral protease inhibitors.

A base labile handle for solid phase organic chemistry

Several arylsulfonamides have been synthesised on solid phase using a new base labile handle. Cleavage front the solid support is accomplished by oxidation of the sulfide to the sulfone, followed by β-elimination in base media.

Discovery of CGS 27023A, a non, peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits

Structure-activity relationships of a lead hydroxamic acid inhibitor of recombinant human stromelysin were systematically defined by taking advantage of a concise synthesis that allowed diverse functionality to be explored at each position in a template. An ex vivo rat model and an in vivo rabbit model of stromelysin-induced cartilage degradation were used to further optimize these analogs for oral activity and duration of action. The culmination of these modifications resulted in CGS 27023A, a potent, orally active stromelysin inhibitor that blocks the erosion of cartilage matrix.